Key TakeawaysU.S. GLP-1 uptake has expanded quickly, but affordability remains a primary barrier, with many insured patients paying full cost and discontinuing therapy due to financial toxicity.Persistence data are heterogeneous, with some claims analyses showing ~two thirds remaining on Wegovy/Zepbound at one year, while other datasets suggest closer to one third.Semaglutide withdrawal data demonstrate two […]
